Method for the treatment of a hyponatremic disease

US5087630A · kind A · utility

Assignee

• Dr Lo Zambeletti S.p.A. · IT

Inventors

• Roberto Colle · Milano, IT
• Antonio Pizzi · Chantraine, FR
• Geoffrey Clarke · Foster City, US

Key dates

• Filing date: Oct 16, 1989
• Grant date: Feb 11, 1992
• Expiry date: Oct 16, 2009

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P7/10
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Compounds of formula (Ia), or pharmaceutically acceptable salts or solvates thereof, ##STR1## in which A, together with the nitrogen atom, represents --(CH.sub.2)p--, where p is an integer from 3 to 6, or an optionally substituted tetrahydroisoquinoline ring system; PA0 each of R.sub.1 and R.sub.2 are independently hydrogen, C.sub.1-6 alkyl, C.sub.2-6 alkenyl C.sub.3-6 cycloalkyl or C.sub.4-12 cycloalkylalkyl, or together form a C.sub.2-6 polymethylene or C.sub.2-6 alkenylene group, optionally substituted with a hetero-atom, PA0 R.sub.x is hydrogen, C.sub.1-6 alkyl or phenyl, or together with R.sub.1 forms a --(CH.sub.2).sub.3 -- or --(CH.sub.2).sub.4 -- group; and R comprises a substituted or unsubstituted carbocyclic or heterocyclic aromatic group; and compounds of formula (Ib) ##STR2## in which: R, R.sub.1, R.sub.2 and X are as defined in formula (Ia) PA0 R.sub.a is C.sub.1-6 alkyl or phenyl; PA0 R.sub.b is hydrogen or together with R.sub.a forms a --(CH.sub.2).sub.n -- group in which n=1, 2 or 3; and PA0 `Het` is an optionally substituted single or fused ring heterocyclic group containing from 5 to 12 ring atoms and comprising up to four hetero-atoms in the or each ring, select…